Novel modalities and the regulatory pathways to clear their journey to patients are driving developments in rare disease treatments in 2025. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from three key opinion leaders across the industry about advancements in oncology and other areas, and the increasing role of patients' families in accelerating R&D.
All content for Drug Solutions is the property of Pharm Tech and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Novel modalities and the regulatory pathways to clear their journey to patients are driving developments in rare disease treatments in 2025. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from three key opinion leaders across the industry about advancements in oncology and other areas, and the increasing role of patients' families in accelerating R&D.
In this episode of the Drug Solutions Podcast, Shawn Liu, the president and CEO of Avirmax, relates his experience in entering the cell and gene therapy manufacturing space and how he began his own startup cell and gene therapy CDMO.
SPONSOR: Lonza
Drug Solutions
Novel modalities and the regulatory pathways to clear their journey to patients are driving developments in rare disease treatments in 2025. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from three key opinion leaders across the industry about advancements in oncology and other areas, and the increasing role of patients' families in accelerating R&D.
